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Background: Type 2 diabetes (T2D) is associated with increased risk of morbidity and premature mortality. Among
those at high risk, incidence can be halved through healthy changes in behaviour. Information about genetic and
phenotypic risk of T2D is now widely available. Whether such information motivates behaviour change is unknown.
We aim to assess the effects of communicating genetic and phenotypic risk of T2D on risk-reducing health
behaviours, anxiety, and other cognitive and emotional theory-based antecedents of behaviour change.
Methods: In a parallel group, open randomised controlled trial, approximately 580 adults born between 1950 and
1975 will be recruited from the on-going population-based, observational Fenland Study (Cambridgeshire, UK).
Eligible participants will have undergone clinical, anthropometric, and psychosocial measurements, been genotyped
for 23 single-nucleotide polymorphisms associated with T2D, and worn a combined heart rate monitor and
accelerometer (ActiheartW) continuously for six days and nights to assess physical activity. Participants are
randomised to receive either standard lifestyle advice alone (control group), or in combination with a genetic or a
phenotypic risk estimate for T2D (intervention groups). The primary outcome is objectively measured physical
activity. Secondary outcomes include self-reported diet, self-reported weight, intention to be physically active and
to engage in a healthy diet, anxiety, diabetes-related worry, self-rated health, and other cognitive and emotional
outcomes. Follow-up occurs eight weeks post-intervention. Values at follow-up, adjusted for baseline, will be
compared between randomised groups.
Discussion: This study will provide much needed evidence on the effects of providing information about the
genetic and phenotypic risk of T2D. Importantly, it will be among the first to examine the impact of genetic risk
information using a randomised controlled trial design, a population-based sample, and an objectively measured
behavioural outcome. Results of this trial, along with recent evidence syntheses of similar studies, should inform
policy concerning the availability and use of genetic risk information.
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Type 2 diabetes (T2D) is associated with costly complica-
tions including cardiovascular disease, neuropathy, and
blindness, as well as premature mortality [1]. Previous re-
search has demonstrated that the development of T2D
can be prevented through healthy changes in behaviour,
even among those at high risk [2]. More specifically, sev-
eral randomised controlled trials including individuals
with impaired glucose tolerance, have reported reductions
in risk by as much as 40% to 60% following interventions
to promote moderate weight loss through a combination
of changes in physical activity and diet [3].
There are many well-established risk factors for T2D, in-
cluding demographic (age and sex), metabolic (obesity),
and behavioural factors (physical inactivity and poor diet)
[1]. Evidence from twin and family history studies has
shown that genetic factors also play an important role in
determining individual susceptibility [4]. While it has been
estimated that between 30% and 70% of T2D risk can be
attributed to genetic factors, until recently, the number of
genes involved and the extent to which each contributes
to the development of the disease remained largely un-
known [4,5]. However, with the implementation of large-
scale studies of genetic association, our understanding has
greatly increased [4,5]. To date, more than 40 single nu-
cleotide polymorphisms (SNPs) associated with increased
risk of T2D have been identified [6–12].
Along with the discovery that several genetic loci are
associated with T2D came an expectation that this infor-
mation would lead to improved prediction of disease risk
[13–16]. Multiple risk models that incorporate routinely
collected data (e.g., sex, age, body mass index, parental
history of T2D, drug treatment, and smoking status)
have already been shown to predict the risk of develop-
ing T2D reasonably well [17,18]. However, contrary to
expectations, there currently appears to be little add-
itional predictive benefit from incorporating genetic in-
formation into non-genetic risk models [17–19]. A
recent meta-analysis of published data on T2D risk pre-
diction showed that the predictive value of SNPs asso-
ciated with T2D was significantly poorer than the
predictive value of non-genetic risk models, with the
area under the receiver operating characteristic curve
ranging from 0.59 to 0.60 and from 0.78 to 0.89, respect-
ively [19]. Furthermore, when genetic information was
incorporated into non-genetic risk models, no clinically
significant improvements in the models’ predictive
values were observed. In spite of these findings, direct-
to-consumer genetic tests that claim to predict suscepti-
bility for T2D are now widely available [20], and some
researchers are optimistic that this information might
enhance preventive strategies [13,21,22].
Consistent with health behaviour theory, it has been
suggested that informing individuals of their geneticrisk of T2D may motivate engagement in risk-reducing
health behaviours (i.e., increased physical activity and a
healthy diet) [23,24]. It is thought that genetic risk infor-
mation could be perceived as more personally relevant
than risk information based on other markers of disease.
Individuals who are informed that they are at increased
risk based on their genotype may consequently have
greater motivation to change their behaviour than those
informed of increased risk based upon another less sali-
ent method (e.g., phenotypic characteristics), or those
informed of a low risk. In contrast, it has also been sug-
gested that informing individuals of their genetic risk of
T2D might de-motivate some to change their behaviour
[24,25]. They could perceive their risk as being uncon-
trollable due to its genetic determinants, which are often
thought to be immutable [26]. Those informed of a high
risk as determined by their genotype might consequently
adopt a sense of fatalism, and those informed of a low
risk might be falsely reassured. In both instances, such
attitudes would likely result in a lack of motivation to
change behaviour.
In order to take full advantage of the motivational impact
of genetic risk information, a deeper understanding of the
mechanisms through which it may motivate behaviour
change is necessary [23]. Several health behaviour theories,
including the Protection Motivation Theory (PMT), indi-
cate that engagement in risk-reducing health behaviours is
largely influenced by an individual’s pre-existing perception
of risk [27,28]. Although there has been much research on
the role of perceived risk as a determinant of behaviour,
how individuals construct their perception of risk and the
extent to which it directly influences behaviour remains
unclear [28–30]. The most common method used for
assessing perceived risk is through self-report of absolute
risk, which is often numerically based [31]. Studies have
shown, however, that individuals experience difficulty
understanding risk estimates based on numerical presenta-
tions of probability or relative risk [32]. Although this may
be due in part to problems of numeracy [33,34], some re-
search suggests that it is because individuals construct their
perception of risk in ways that are not entirely rational
[30,32,35]. The Common Sense Model of self-regulation of
health and illness (CSM) provides a framework for under-
standing how perceived risk is constructed [36]. Previous
research highlights the importance of using the CSM as
the conceptual basis for identifying the content and influ-
ences of perceived risk [32], and also supports examining
the utility of the PMT to predict changes in behaviour
[37,38]. Together, the CSM and the PMT could elucidate
which components of T2D risk information effectively mo-
tivate change in risk-reducing health behaviours.
To date, no research has examined the effect of com-
municating genetic risk of T2D on the risk-reducing
health behaviours of physical activity and diet. The
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cused on diseases that have single-allele associations and
do not have complex gene-lifestyle interactions [39,40].
A recent systematic review by Marteau et al. [39], identi-
fied seven randomised controlled trials and six analogue
studies that evaluated the effects of providing genetic
risk information for a range of diseases (e.g., lung cancer,
heart disease, and Alzheimer’s disease). The studies
explored a variety of behavioural outcomes (e.g., smok-
ing cessation, medication adherence, and vitamin use),
many of which were assessed through imprecise self-
report measures. Only two of the trials included in the
review assessed self-reported changes in physical activity
and diet, and neither was in the context of T2D. In line
with the findings of similar reviews [41–44], the authors
concluded that the limited number of low quality studies
precluded strong statements regarding the effect of com-
municating genetic risk information on non-clinical risk-
reducing behaviours. There was no evidence that genetic
risk information de-motivated individuals. However, it
does appear that genetic risk information may not
greatly motivate behaviour change, but may have a small
effect on intentions to change behaviour [39]. Given the
rapid growth in our understanding of the genetic basis
of complex disease and the increasingly widespread
availability of genetic tests, there is a pressing need to
improve our knowledge of the potential for beneficial or
harmful effects of informing people of their genetic risk
of disease [45,46].Figure 1 The flow of participants through the Diabetes Risk CommunObjectives
The primary objective of the Diabetes Risk Communica-
tion Trial (DRCT) is to assess whether communicating a
genetic risk estimate for T2D in combination with
standard lifestyle advice motivates greater changes in ob-
jectively measured physical activity than a phenotypic
risk estimate for T2D in combination with standard life-
style advice or standard lifestyle advice alone.
The secondary objectives are to determine the effects
of the interventions on self-reported diet; self-reported
weight; intentions to be physically active and to engage
in a healthy diet; anxiety; diabetes-related worry; self-
rated health; and other cognitive and emotional theory-
based antecedents to behaviour change.
Methods
Study design
The DRCT is a parallel group, open randomised controlled
trial with allocation of approximately 580 participants to
one of three groups. Participants in each group receive
standard lifestyle advice, which includes general informa-
tion about T2D as well as information about how to reduce
the risk of developing the disease. In addition to this infor-
mation, one group receives a genetic risk estimate for T2D,
while another group receives a phenotypic risk estimate
(intervention groups). The remaining group of participants
(control group) does not receive either of the risk estimates
until after they have completed follow-up. The design of
the trial and flow of participants are shown in Figure 1.ication Trial.
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Participants are recruited from the Fenland Study, an on-
going population-based, observational study investigating
the influence of lifestyle and genetic factors on the devel-
opment of diabetes, obesity, and other metabolic disorders
[47]. Residents of Cambridgeshire, in the east of England,
born between 1950 and 1975 are potentially eligible to
participate in the Fenland Study and are excluded by their
general practitioner if they have been diagnosed with dia-
betes or a terminal illness with a prognosis of less than
one year. Additionally, they are excluded if they suffer
from a psychotic illness, are pregnant or lactating, or if
they are unable to walk unaided. Approximately 28% of
those registered with participating general practices in the
Cambridgeshire Primary Care Trust have enrolled in the
Fenland Study (more than 8,000 participants). Fenland
Study participants visit a study centre where they undergo
a health assessment. Blood samples are taken for the
genotyping of SNPs associated with T2D. At the end
of the assessment, Fenland Study participants are fitted
with a combined heart rate monitor and accelerometer
(described in detail below), which they are instructed to
wear continuously for six days and nights prior to return-
ing it to the study centre.
Participants of the Fenland Study are invited to take part
in the DRCT if they have given permission to be contacted
regarding potential involvement in future studies. Further-
more, they must have provided sufficient data to calculate
their genetic and phenotypic risk estimates for T2D
(described in detail below), and have worn the combined
heart rate monitor and accelerometer for three or more
full days without experiencing a severe skin reaction.
Lastly, the monitor must have recorded at least 36 hours
of complete data. Fenland Study participants who fulfil
the inclusion criteria are invited to take part in the DRCT
in the order in which they completed their health assess-
ment (median 1.76 years prior to being invited), beginning
with the most recent first. Potential participants are
mailed an invitation letter, a study brochure, a sample
consent form, and a response form. Those interested in
taking part are asked to complete the response form and
to return it in the enclosed freepost reply envelope. In the
event of non-response, a second mailing is sent approxi-
mately four weeks after the first. Responders are excluded
from the DRCT if they have been diagnosed with diabetes
or are actively participating in another study. The exclu-
sion criteria are explicitly stated in both the invitation
letter and the study brochure, and are assessed in the re-
sponse form via self-report.
Baseline assessment
All baseline information is collected prior to randomisa-
tion. Responders who are eligible to take part in the
DRCT are sent a baseline instruction letter, a consentform, and a baseline questionnaire. The instruction letter
asks responders to read and sign the consent form prior
to completing the baseline questionnaire. They are then
asked to return both documents in the enclosed freepost
reply envelope. A reminder letter, along with a second
consent form and baseline questionnaire, is sent if the
first consent form and questionnaire are not returned
within two weeks. The measures assessed in the baseline
questionnaire are combined with several measures taken
during the participants’ Fenland Study health assessment
in order to create a comprehensive baseline characterisa-
tion of the study population.
Randomisation, allocation concealment and blinding
In order to ensure equal allocation across the three trial
groups, participants are allocated to one of the groups
using a blocked randomisation procedure. A statistician
without knowledge of participant characteristics created a
computer-generated list comprised of blocks of six that
contain two of each of the three trial groups per block in a
random order. The randomisation list was incorporated
into a computer program that members of the study co-
ordination team use for enrolment and automated ran-
domisation of participants. Allocation is concealed from
the study coordination team, researchers, and participants
until the interventions are assigned. It is not possible to
blind participants to which intervention they receive.
However, researchers assessing the baseline characteristics
of participants and the primary outcome of the trial re-
main blinded to group assignment. Additionally, an inde-
pendent, quality assured data-entry company undertakes
all data entry unaware of group allocation.
Intervention
The interventions consist of either a genetic risk estimate
or a phenotypic risk estimate for T2D, both in combin-
ation with standard lifestyle advice (see Appendices A
through C for examples). Several modes of intervention
delivery were considered, including face-to-face counsel-
ling, telephone conversations, and printed materials.
Printed materials were chosen as they have the advantage
of being simple, inexpensive, and do not create any undue
burden for participants in relation to time and travel. Both
interventions contain information presented in a manner
similar to that of several direct-to-consumer genetic test-
ing companies (e.g., www.navigenics.com, www.decodeme.
com, and www.23andme.com), and they were designed to
incorporate evidence regarding the most effective meth-
ods for communicating disease risk estimates. As it
remains unclear whether an individual’s understanding of
risk is more accurate after the provision of a numerical
risk estimate or a verbal risk estimate [34,48], both the
genetic and phenotypic risk estimates include a numerical
(i.e., percentage) and verbal estimation of risk (i.e., “below
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search suggests that comparative risk estimates may have a
greater influence on behaviour than absolute risk estimates
[49,50], and that visual representations of risk elicit greater
recall and understanding of risk [33,34,51]. Thus, estimates
are framed in comparison to the average risk within each
participant’s age and sex specific group, and participants are
told what percentage of Fenland Study participants have a
risk estimate higher, lower, and equal to their own. Each
piece of information is represented using a visual image.
Genetic risk estimate
Trained personnel at a study centre took blood samples
during the Fenland Study. Genomic DNA was extracted
from up to 7.5 ml of whole blood stabilised in EDTA using
an Autopure LS DNA preparation platform (Qiagen,
Crawley, UK). Genotyping was carried out by the Depart-
ment of Pathology, University of Cambridge using the
HumanCardio-Metabo Beadchip Kit supplied by IlluminaW
(Cambridge, UK). The following 23 SNPs were identified
through adequately powered genome-wide association
studies, the associations with T2D reached the genome-
wide significance level (p-values for associations less than
5x10-8), and the associations were replicated in at least one
independently published study: CDKN2A/B rs10811661,
MTNR1B rs10830963, HHEX rs1111875, ZFAND6
rs11634397, ADCY5 rs11708067, SLC30A8 rs13266634,
CENDT2 rs1552224, DGKB/TMEM195 rs2191349,
KCNQ1 rs231362, ADAM30 rs2641348, PROX1 rs340874,
IGF2BP2 rs4402960, ADAMTS9 rs4607103, ZBED3
rs4457053, CDKN2A/B rs564398, NOTCH2 rs10923931,
IRS1 rs7578326, CDKAL1 rs7756992, GCKR rs780094,
TCF7L2 rs7903146, JAZF1 rs864745, TP53INP1 rs896854,
and VEGFA rs9472138 [6–12]. All SNPs were in Hardy-
Weinberg equilibrium (χ2, P> 0.05). Occasionally, one or
more may have been missing due to random error in the
genotyping process. In these cases, linkage disequilibrium
was taken advantage of in order to impute the genotype at
the loci for which data were missing. The odds ratio for
each SNP included in the estimation of genetic risk was
taken from replication samples, and the allele frequency
was taken from the HapMap population.
The genetic risk estimate is presented as an estimate of
the participant’s lifetime risk of developing T2D. It was
calculated using the aforementioned genetic data and pro-
cedures outlined in literature published by several direct-
to-consumer genetic testing companies (see Appendix D
for an example) [52–54]. First, assuming a multiplicative
model, the odds ratio for the risk allele of each SNP asso-
ciated with T2D and the corresponding population fre-
quency of the risk allele were used to determine the odds
ratios and frequencies of the three possible genotypes at
each locus. Next, the average population risk at each
locus, relative to the no risk genotype, was calculated bysumming the product of the genotype specific odds ratios
and frequencies. Each genotype specific odds ratio was then
divided by the average population risk at each locus in
order to derive an estimate of the genotype specific risk that
is relative to the average population risk at each locus. The
genotype specific risks were then combined using a multi-
plicative model to create a total genetic risk relative to the
population for each participant. Lastly, the participant’s total
genetic risk was multiplied by their corresponding age and
sex specific T2D residual lifetime risk estimate [55].
Phenotypic risk estimate
Age, sex, family history of diabetes, smoking status, and
prescription of steroid or anti-hypertensive medication were
assessed through self-report during the Fenland Study.
Height and weight were also measured using standardised
procedures [47], and body mass index was calculated as
weight (kg) divided by the square of height (m) [56].
The phenotypic risk estimate is presented as an estimate
of the participant’s lifetime risk of developing T2D. It was
calculated using the aforementioned phenotypic data and
the Cambridge Diabetes Risk Score [57], which has been
previously validated in the EPIC-Norfolk study, where it
was shown to provide good prediction of incident T2D
(area under the receiver operating characteristic curve
equal to 0.75) [58]. First, each participant’s T2D risk score
was calculated (from 0 to 1) using the published beta-
coefficients from the Cambridge Diabetes Risk Score.
Next, the natural logarithm of the score was taken and the
results were stratified into age and sex specific groups.
Lastly, the percentage difference from the mean was cal-
culated for each participant and the resulting percentage
was multiplied by their corresponding age and sex specific
T2D residual lifetime risk estimate [55]. Calculating the
phenotypic risk estimates in this way generated values that
were broadly similar to the genetic risk estimates.
Standard lifestyle advice
All participants receive general information about T2D
irrespective of risk and group assignment. The informa-
tion includes a brief description of T2D and an explan-
ation of the risk factors, symptoms, diagnosis, treatment,
and consequences of the disease. All participants are
told that the likelihood of developing the disease can be
reduced by following physical activity and dietary guide-
lines. They are equally encouraged to maintain a healthy
weight and to follow government recommendations to
engage in at least 30 minutes of moderate intensity
physical activity on five or more days of the week [59]
and to eat five servings of fruit and vegetables a day [60].
Immediate post-intervention assessment
Following allocation to a trial group, participants are mailed
an intervention instruction letter, standard lifestyle advice
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mediate post-intervention questionnaire. The instruction
letter asks participants to read through the intervention
materials until they feel happy that they understand them,
complete the immediate post-intervention questionnaire,
and return it in the enclosed freepost reply envelope. A re-
minder letter, along with a second copy of the question-
naire, is sent if the first is not returned within two weeks. If
the questionnaire is still not returned after four weeks, a
second reminder letter is sent.
Follow-up assessment
Approximately eight weeks post-intervention, participants
are sent a follow-up instruction letter, a combined heart
rate monitor and accelerometer, and follow-up question-
naires. A member of the study team contacts each partici-
pant by telephone approximately one week before the
monitor is due to be posted to check that it is a conveni-
ent time for them to wear it. If it is an inconvenient time,
an alternative time is arranged. The instruction letter asks
participants to wear the monitor for six days and nights
continuously, and then return it along with the follow-up
questionnaires in the enclosed Special Delivery freepost
reply envelope. A reminder letter is sent if responses are
not received within two weeks. If responses are still not
received after three weeks, a member of the study team
contacts the participant by telephone to arrange for the
monitor to be returned. If necessary, a second telephone
call is made. Upon receipt of the monitor and question-
naires, participants are mailed a study completion letter
and a wait-list response form. The response form asks par-
ticipants to indicate if they would like to be sent which-
ever risk estimate(s) they have not yet received, and
indicates that we will send feedback about their current
physical activity level shortly. They are asked to return the
response form in the enclosed freepost reply envelope. If a
response is not received within two weeks, we send only
the physical activity feedback.
Measures
The primary outcome is objectively measured physical
activity, defined as physical activity energy expenditure
(PAEE, measured in kJ/kg/day). It is assessed using the
ActiheartW, a single-piece monitor capable of measuring
acceleration, heart rate, heart rate variability, and ECG
amplitude for a set time resolution [61]. A sub-maximal
exercise test was conducted as part of the Fenland Study
and is used for individual calibration of heart rate re-
sponse [62]. Branched equation modelling is utilised to
estimate PAEE [63]. This approach has high validity for
estimating the intensity of physical activity [64,65] and
overcomes some of the key limitations associated with
either accelerometers or heart rate monitors alone [61].
Participants are instructed to wear the monitor for sixdays and nights continuously, and to carry on with all
normal activities during this time. The device is non-
invasive, weighs less than 8 g and is worn on the chest
attached to standard ECG electrodes stuck directly onto
the skin. It is only 7 mm thick (33 mm in diameter), and
except for a brief period to change electrodes (every few
days) it does not need to be removed. Monitors are also
waterproof and can be worn while swimming or shower-
ing. These factors make it convenient and discreet to
wear. Participants are also asked to complete an Acti-
heartW log sheet, which indicates the date and time they
a) started wearing the monitor, b) removed it (along with
the reason) and replaced it again, and c) completed
measurement.
All secondary outcomes are measured via self-report
questionnaire and are described in detail in Table 1. They
include self-reported diet, self-reported weight, intentions
to be physically active and to engage in a healthy diet, anx-
iety, diabetes-related worry, self-rated health, and other
cognitive and emotional outcomes that are based on the
PMTand the CSM.
Statistical analysis
We will use univariate descriptive statistics (means,
standard deviations, numbers, and percentages) to sum-
marise the characteristics of the study sample at
baseline. All trial analyses will be performed on an
intention-to-treat basis (i.e., analysis of data according to
randomised study group, regardless of whether or not
the intervention was received). Those with missing out-
come data will be excluded from the analyses (a complete
case approach). If necessary, a sensitivity analysis will be
performed to investigate the effect of having excluded
participants with missing data for the primary outcome
only. We will use a multiple imputation procedure with a
‘missing at random’ assumption to impute missing out-
come data [89]. Participants with missing baseline data
will be included in the analyses using the missing-
indicator method [90].
An analysis of covariance (ANCOVA) regression
model will be used to determine if differences exist in
mean PAEE at follow-up, adjusted for baseline, between
randomised groups. Exploratory analyses will be con-
ducted to examine potential moderators and mediators
of the intervention effects on PAEE (i.e., sex, age, body
mass index, time since the Fenland Study, and baseline
measurements of the trial outcomes). A further sub-
group analysis will explore whether a high or low risk
estimate moderates the effect of type of T2D risk esti-
mate (i.e., genetic or phenotypic) on PAEE. Similar re-
gression analyses will be used to examine differences in
all secondary outcomes. Acceptability will be assessed by
summarising recruitment rates, loss to follow-up, and
reasons for loss to follow-up. Additionally, differences in
Table 1 Measures used in the Diabetes Risk Communication Trial (DRCT)
Measure(s) Brief description Stage assessed
Fenland
study
DRCT
baseline
DRCT post-
intervention
DRCT
follow-up
Demographic characteristics Sex, age, race/ethnicity, immigrant status, level of education,
employment status, and level of income were assessed
through self-report.
✓
Anthropometric, body composition,
clinical, physical activity, biochemical,
medical history, and lifestyle
Anthropometric (e.g., height, weight, hip and waist), body
composition (e.g., precise body fat percentage and
distribution using ultrasound and DEXA), clinical (e.g., blood
pressure and pulse rate), and physical activity measurements
(e.g., heart rate, movement, and oxygen consumption at rest
and during a sub-maximal treadmill test) were assessed by
trained staff. An oral glucose tolerance test was administered,
and two blood samples were taken to assess glucose levels
and blood lipids. Medical history and general lifestyle were
assessed through self-report.
✓
Perceived healthy weight Participants are asked what they think a healthy weight is for
them in either stones or kilograms. This measure has been
used in previous research [66].
✓
Perceived weight status Participants are asked if they think that they are underweight,
overweight, or an acceptable weight. This measure has been
used in previous research [67,68]
✓
Perception of diet 1) Participants are asked how much fruit and vegetables they
think that they eat compared to people of their age and sex,
and answer on a 5-point response scale, ranging from “much
less” to “much more”. 2) Participants are asked whether or not
they meet the national recommendations for fruit and
vegetable consumption. Similar measures have been used in
previous research [69,70].
✓
Perception of physical activity 1) Participants are asked how physically active they think that
they are compared to people of their age and sex, and
answer on a 5-point response scale, ranging from “much less”
to “much more”. 2) Participants are asked whether or not they
meet the national guidelines for engagement in physical
activity. Similar measures have been used in previous research
[71,72].
✓
History of genetic testing Participants are asked if they have ever had a genetic test to
assess their risk of developing a disease, and if so, to list the
disease(s) for which their risk was assessed.
✓
Process measures Participants are asked what they think that their risk estimate
showed, how accurate they think that their risk estimate is,
whether or not they have kept their risk estimate, and
whether or not they have discussed their risk estimate with
someone. Additionally, participants are asked if they
previously had a genetic test to assess their risk of developing
a disease, and if so, to list the disease(s) for which their risk
was assessed.
✓
Diabetes risk representations* Assessed using the Brief Illness Perceptions Questionnaire
(Brief IPQ) [73]. The Brief IPQ consists of 8 items that address
the cognitive and emotional illness representations in the
CSM. To capture representations of T2D risk held by healthy
individuals, the items have been adapted according to
methods used in previous research [74,75]. The Brief IPQ has
been shown to have good test-retest reliability and to be
highly correlated with relevant subscales of the IPQ-R [73].
✓ ✓
Self-efficacy, response efficacy,
and perceived severity*
Assessed using 10 Likert items. Each item includes a statement
(e.g., “I am confident that I could be more physically active if I
wanted to”) evaluated on a 5-point response scale, ranging
from “strongly disagree” to “strongly agree”. These items have
been adapted for use in the context of T2D [76,77] and have
been used in previous research [78].
✓ ✓
Perceived risk* 1) Participants are asked how likely they think that they are to
get T2D in the next 10 years and their lifetime, and first
✓ ✓ ✓
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Table 1 Measures used in the Diabetes Risk Communication Trial (DRCT) (Continued)
answer on a 5-point response scale, ranging from “very
unlikely” to “very likely”, and then on a continuous scale,
ranging from 1 to 100. 2) Participants are asked how likely
they think they are to get T2D in the next 10 years and their
lifetime, compared to people their same age and sex, and
answer on a 5-point response scale, ranging from “much less
likely” to “much more likely”. These items have been adapted
according to recommendations provided by Diefenbach et al.
[79], and have been used in previous research [80].
Self-rated health* Participants are asked if they think that their overall health is
excellent, good, fair, or poor. This measure has been used in
previous research [81].
✓ ✓
Diabetes-related worry* Assessed using the Cancer Worry Scale (CWS) [82]. The CWS
consists of 6 items that assess the frequency of worries about
developing cancer and the effect that these worries have on
mood and daily functioning. These items have been adapted
for use in the context of T2D and have been shown to have
acceptable test-retest reliability and good internal consistency
[83].
✓ ✓
Anxiety* Assessed using the short-form of the state scale of the
Spielberger State Trait Anxiety Inventory (STAI) [84]. The short-
form STAI consists of 6 items that comprise the most highly
correlated anxiety-present and anxiety-absent items from the
full-form of the STAI. Scores obtained using this short-form
have been shown to be highly correlated with scores
obtained using the full-form of the STAI [84].
✓ ✓ ✓
Intentions to be physically active
and engage in a healthy diet*
Assessed using 4 items. Each item includes a statement (e.g., “I
intend to be more physically active in the next 8 weeks.”)
evaluated on a 5-point response scale, ranging from “extremely
unlikely” to “extremely likely”. These items have been adapted
according to recommendations provided by Ajzen [77] and
have been used in previous research [78,85].
✓ ✓ ✓
Self-reported weight* Participants are asked what their current weight is, without
shoes, in either stones or kilograms. Detailed descriptions of
the reliability and validity of self-reported weight have been
published elsewhere [86].
✓ ✓
Self-reported diet* Assessed using the Food Frequency Questionnaire (FFQ) [87].
The FFQ contains a list of 130 foods, including 12 fruit items
and 26 vegetable items. Only the fruit and vegetable items
are assessed at follow-up. Detailed descriptions of the
reliability and validity of the FFQ have been published
elsewhere [87,88].
✓ ✓
*Secondary outcomes.
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of the risk estimates, as well as the retention and discus-
sion of the risk estimates will be examined.
Sample size
Estimates used in the sample size calculation were taken
from the FAB study, which had a similar sample population
and the same primary outcome to that proposed here (i.e.,
PAEE) [91]. The mean (standard deviation) PAEE at follow-
up in the FAB study was 46.2 (15.4) kJ/kg/day, and the cor-
relation between baseline and follow-up was high (0.69).
After making a Bonferroni adjustment for multiple compar-
isons in a three group trial, we determined that in order to
detect a between-group difference of 4.1 kJ/kg/day in PAEE
at follow-up (which equates to approximately 20 to 25 min-
utes of brisk walking per day), with a significance level of1.67% and 80% statistical power, approximately 465 partici-
pants will need to complete the trial. Thus, allowing for an
attrition rate of 20%, we aim to randomise approximately
580 participants.
Data management and quality assurance
Each participant is assigned a unique numeric identifier
at the beginning of the Fenland Study so that they can
be tracked without reference to personal information. A
new identifier is assigned to participants enrolled in the
DRCT, and a data manager uninvolved in data collection
maintains a link to the corresponding Fenland Study
identifier. All personal data are stored on an encrypted
drive, and links to personal information are only avail-
able to the study coordination team. Consent forms and
questionnaire data are stored in locked filing cabinets in
Godino et al. BMC Public Health 2012, 12:444 Page 9 of 11
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double entered by an independent, quality assured data-
entry company.
Trained personnel conduct the trial according to the
standard operating procedures established by the MRC
Epidemiology Unit and the principles of good clinical
practice [92]. Standardised delivery of the interventions
is assured by having one member of the study coordin-
ation team prepare the intervention materials using an
automated computer program. A second member veri-
fies that the intervention materials are correct prior to
sending them to participants.Ethics
Full ethical approval for the Fenland Study was obtained
from the Cambridge Local Research Ethics Committee on
the 11th of May 2004 (reference number 04/Q0108/19).
Full ethical approval for the DRCT was obtained from the
Cambridgeshire 1 Research Ethics Committee on the 21st
of October 2010 (reference number 10/H0304/78). Writ-
ten informed consent is obtained from all participants,
and each participant’s general practitioner is notified of
their enrolment.Discussion
To enhance our understanding of the effects of communi-
cating information about genetic and phenotypic risk of
T2D on risk-reducing health behaviours, larger and higher
quality randomised controlled trials are needed [39]. Such
trials will have the power to detect small, but still clinically
important, effect sizes while allowing for a more compre-
hensive analysis of potential mediators and moderators of
effects of risk communication. Studies should include pre-
cise measures of behaviours and behavioural intentions, a
comprehensive assessment of individual risk perception,
and a sound theoretical framework so as to further eluci-
date the motivational impact of risk communication. Each
of these recommendations is consistent with the MRC
Framework for the development and evaluation of com-
plex interventions to improve health [93], and highlight
the strengths of this study.
Previous research has demonstrated that healthy changes
in behaviour can significantly reduce the incidence of T2D,
even among those at high risk [2]. However, translation of
these findings into preventive strategies has proven diffi-
cult, as it requires that individuals are motivated to adopt
and maintain the behavioural changes necessary to prevent
T2D [94]. The DRCT will provide robust evidence of the
potential for beneficial or harmful effects of communicat-
ing genetic and phenotypic risk information on risk-
reducing health behaviours and the potential role of such
information in T2D preventive strategies.Abbreviations
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